HC Wainwright Forecasts Cytokinetics Q1 Earnings

Cytokinetics, Incorporated (NASDAQ:CYTK) – Equities research analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of Cytokinetics in a report issued on Friday, February 28th. HC Wainwright analyst J. Pantginis forecasts that the biopharmaceutical company will post earnings of ($1.42) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $120.00 price target on the stock. The consensus estimate for Cytokinetics’ current full-year earnings is ($5.24) per share. HC Wainwright also issued estimates for Cytokinetics’ Q2 2025 earnings at ($1.44) EPS, Q3 2025 earnings at ($1.44) EPS, Q4 2025 earnings at ($1.53) EPS and FY2025 earnings at ($5.83) EPS.

Cytokinetics (NASDAQ:CYTK) last released its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($1.26) EPS for the quarter, beating the consensus estimate of ($1.29) by $0.03. The firm had revenue of $16.93 million during the quarter, compared to the consensus estimate of $14.26 million.

CYTK has been the subject of several other reports. Evercore ISI upgraded Cytokinetics to a “strong-buy” rating in a research note on Friday, February 7th. Mizuho upped their price objective on shares of Cytokinetics from $99.00 to $103.00 and gave the stock an “outperform” rating in a research report on Thursday, November 21st. Stifel Nicolaus assumed coverage on shares of Cytokinetics in a report on Wednesday, January 22nd. They set a “buy” rating and a $80.00 price target for the company. JMP Securities reaffirmed a “market outperform” rating and issued a $78.00 target price on shares of Cytokinetics in a report on Friday, February 7th. Finally, Royal Bank of Canada raised their price target on shares of Cytokinetics from $80.00 to $82.00 and gave the company an “outperform” rating in a research note on Wednesday, December 18th. Two investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Cytokinetics currently has a consensus rating of “Moderate Buy” and an average target price of $82.00.

Cytokinetics Stock Down 6.8 %

CYTK opened at $42.89 on Monday. The company has a current ratio of 9.28, a quick ratio of 9.28 and a debt-to-equity ratio of 5.93. The stock has a market cap of $5.06 billion, a PE ratio of -7.97 and a beta of 0.83. The stock’s fifty day simple moving average is $47.10 and its 200 day simple moving average is $51.12. Cytokinetics has a 1-year low of $40.53 and a 1-year high of $75.71.

Insider Activity

In other Cytokinetics news, EVP Fady Ibraham Malik sold 7,300 shares of the firm’s stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $50.64, for a total transaction of $369,672.00. Following the transaction, the executive vice president now directly owns 116,071 shares in the company, valued at approximately $5,877,835.44. This trade represents a 5.92 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director John T. Henderson sold 1,780 shares of the business’s stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $50.42, for a total transaction of $89,747.60. Following the transaction, the director now owns 38,461 shares in the company, valued at approximately $1,939,203.62. This trade represents a 4.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 17,822 shares of company stock worth $874,048 in the last three months. Company insiders own 3.40% of the company’s stock.

Institutional Investors Weigh In On Cytokinetics

Several large investors have recently made changes to their positions in the business. GF Fund Management CO. LTD. bought a new stake in Cytokinetics in the 4th quarter valued at about $117,000. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. bought a new position in Cytokinetics in the 4th quarter worth about $15,483,000. Vestal Point Capital LP boosted its position in shares of Cytokinetics by 56.7% during the 4th quarter. Vestal Point Capital LP now owns 2,350,000 shares of the biopharmaceutical company’s stock valued at $110,544,000 after acquiring an additional 850,000 shares during the last quarter. Two Sigma Advisers LP grew its holdings in shares of Cytokinetics by 5.4% during the fourth quarter. Two Sigma Advisers LP now owns 226,400 shares of the biopharmaceutical company’s stock worth $10,650,000 after purchasing an additional 11,700 shares in the last quarter. Finally, Teza Capital Management LLC bought a new stake in Cytokinetics during the fourth quarter valued at approximately $446,000.

Cytokinetics Company Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.